Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.
The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
The companies will offer a system for the identification and quantitation of metabolites in biological samples.
The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
The Triple Quad 4500MD LC-MS/MS system, which consists of the LC-MS/MS platform along with Sciex's Analyst MD, Cliquid MD, and MultiQuant MD software, can be used for in vitro diagnostics.
As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.
With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.
While DIA methods like Swath have seen rapid uptake in proteomics, some core labs have struggled to add these workflows to their fee-for-service offerings.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."
Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.
Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.